All News
Triple Hormone Receptor Agonist for Treatment of Obesity and Knee Osteoarthritis
The NEJJM reports that Retatrutide, an investigational incretin agent, was shown to
Remission – Believe it or Not (10.2.2026)
Dr, Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
Supervised Physiotherapy Wins after ACL Repair
The Annals of Internal Medicine has shown that chronic knee symptoms following anterior cruciate ligament reconstruction (ACLR) surgery is significantly lessened by a program of physiotherapist-supervised exercise therapy with education compared to single education and self-directed exer
Read Article
Link Between Obesity and Psoriatic Arthritis
Obesity is an incidental comorbidity in psoriatic arthritis (PsA). It is a modifiable, mechanistically active driver of disease onset, severity, and treatment failure. A new comprehensive review in RMD Open (Madsen et al., 2026) synthesizes 49 studies suggesting that weight management belongs in the core PsA treatment algorithm.
Read Article
Mediterranean Diet Lowers Incident Rheumatoid Arthritis Risk
The American Journal of Clinical Nutrition has published the results of the SUN Project study, showing that long-term adherence to a Mediterranean diet (MedDiet) was associated with a substantially lower risk of incident rheumatoid arthritis (RA), but not psoriasis.
Read Article
Merck MSD announced positive results w/ tulisokibart (anti-TL1A) in MK-7240-012, Phase 2b DBRPCT in mod-severe hidradenitis suppurativa. Wk 16 HiSCR50 responses were 72% (hi dose), 64% (mid dose), 52% (low dose) vs 35% PBO. https://t.co/cvBH0fvCnI https://t.co/jo7JaXMItZ
Dr. John Cush RheumNow ( View Tweet)
BMJ reports TriNetX EHR study showing GLP-1 RA use in knee OA pts was assoc w/ significantly lower cumulative TKA incidence (p<0.001). 1 year any GLP-1 RA (HR 0.90) or 3 yrs exposure (HR 0.72) signif lowered TKA 8 yrs later https://t.co/RGQJJHgLFv https://t.co/Ko7VI3ZAC0
Dr. John Cush RheumNow ( View Tweet)
Cluster analysis of Spanish RELES #SLE SLE cohort reveals 3 groups. C1 (n 168) was younger, w/ lupus nephritis, low C3, intensive Rx, high infx & damage. C2 (175) w/ cytopenias, serositis, APL & dsDNA(+). C3 (452) mild skin-Jts, less serologic activity & complications https://t.co/N0XLUaegWc
Dr. John Cush RheumNow ( View Tweet)
J&J announced topline results of Phase 4 STAR study where guselkumab (Tremfya) improved in axial Sxs & MRI outcomes in 411 biologic-naïve axial PsA pts, STAR is a 24 wk DBPCT of GUS (IL-23 inhib) in DMARD unresponsive pts. Endpoint was BASDAI @ wk24. https://t.co/LkqwV0zRmn https://t.co/gZuuQ4jcEf
Dr. John Cush RheumNow ( View Tweet)
Supervised Physiotherapy Wins after ACL Repair
The Annals of Internal Medicine has shown that chronic knee symptoms following anterior cruciate ligament reconstruction (ACLR) surgery is significantly lessened by a program of physiotherapist-supervised exercise therapy with https://t.co/8HWmkmIexr
Dr. John Cush RheumNow ( View Tweet)
Observational study of 228 #PsA pts Rx biologics, either early (<2yrs; mean 6 mos) vs later (mean 3.6 yrs). Groups were balanced in all parameters; after 6 mos no diff in DAPSA50 or PASI75 response. Biologics work regardless of when started. https://t.co/ZCDR8l2CsI https://t.co/PHgtgZu12G
Dr. John Cush RheumNow ( View Tweet)
Obesity & Biologic Treatment Response
Prepared for "The Obesity Imperative" campaign.
https://t.co/72TFW6BWgG https://t.co/XWFWoH2D33
Dr. John Cush RheumNow ( View Tweet)
Bringing TOGETHER-PsA Into Clinical Practice
The TOGETHER-PsA trial provides prospective evidence supporting an integrated approach to PsA and weight management, reinforcing the importance of addressing both inflammatory disease activity and metabolic health as part of https://t.co/WmF4mdxDWR
Dr. John Cush RheumNow ( View Tweet)
The Need for Weight Loss and Weight Gain in the ILD Clinic
https://t.co/UaKW9GPJTN https://t.co/QGYblSxbfP
Dr. John Cush RheumNow ( View Tweet)
BMJ reports TriNetX EHR study showing GLP-1 RA use in knee OA pts was assoc w/ significantly lower cumulative TKA incidence (p<0.001). 1 year any GLP-1 RA (HR 0.90) or 3 yrs exposure (HR 0.72) signif lowered TKA 8 yrs later https://t.co/RGQJJHgLFv https://t.co/BoSgFoOyNN
Dr. John Cush RheumNow ( View Tweet)
Residual steroids doesnt preserve remission. Japan FRANK #RA registry 411/3,863 were in Boolean remission - 130 on GC vs 231 non-GC (1/3 on b/tsDMARDs). Roughly 1/3 flared to LDA @12 mos. Outcomes same for GC vs non-GC Rx pts. https://t.co/xPctEjFCLT https://t.co/YIHFaQkzeO
Links:
Dr. John Cush RheumNow ( View Tweet)
J&J announced topline results of Phase 4 STAR study where guselkumab (Tremfya) improved in axial Sxs & MRI outcomes in 411 biologic-naïve axial PsA pts, STAR is a 24 wk DBPCT of GUS (IL-23 inhib) in DMARD unresponsive pts. Endpoint was BASDAI @ wk24. https://t.co/LkqwV0zRmn https://t.co/2Tdg96rWFX
Dr. John Cush RheumNow ( View Tweet)
Obesity and Psoriatic Disease
Obesity is a clinically important comorbidity in psoriasis (PsO) and psoriatic arthritis (PsA). Excess adiposity contributes to systemic inflammation and cardiometabolic risk and may adversely affect disease severity and response to some systemic https://t.co/WVIqfq8vEj
Dr. John Cush RheumNow ( View Tweet)
Rheum Survey: Beyond weight loss, How will GLP-1 drugs benefit rheumatic pts?
Dr. John Cush RheumNow ( View Tweet)
FDA FAERS pharmacovigilance study of MSK serious adverse reports w/ GLP-1 RAs - Muscle atrophy showed the strongest AE, w/ less freq reports of back pain, muscle spasms, neck pain. https://t.co/4xRH6yWH1o https://t.co/MKCKtkFd1u
Dr. John Cush RheumNow ( View Tweet)
